Drug intelligence / Profile preview

calcium folinate + recombinant human endostatin + fluorouracil + irinotecan

Development stage
Unknown
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

This drug is a combination chemotherapy regimen consisting of four components: - **Calcium folinate** (also known as leucovorin or folinic acid): a vitamin derivative that enhances the effectiveness of fluorouracil by stabilizing its binding to the target enzyme. - **Recombinant human endostatin**: an anti-angiogenic agent that inhibits tumor blood vessel formation, thereby restricting tumor growth. - **Fluorouracil (5-FU)**: a pyrimidine analog chemotherapy drug that interferes with DNA synthesis in rapidly dividing cancer cells. - **Irinotecan**: a topoisomerase I inhibitor chemotherapy drug that prevents DNA replication and transcription in cancer cells. The combination is used primarily for treatment of advanced or metastatic cancers such as colorectal cancer and gastric cancer. Calcium folinate improves the efficacy of fluorouracil. Recombinant human endostatin adds an anti-angiogenic mechanism to inhibit tumor vascularization, complementing the cytotoxic effects of fluorouracil and irinotecan.

02

Targets

ITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on calcium folinate + recombinant human endostatin + fluorouracil + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on calcium folinate + recombinant human endostatin + fluorouracil + irinotecan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call